Cannabis Law Report
APRIL 8, 2022
To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Lyle Craker, Ph.D., million in the form of a bequest.
The Cannigma
SEPTEMBER 12, 2021
Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. If you have a family history of addiction, or suffer from mental conditions such as depression and schizophrenia, you should carefully consider whether or not cannabis is right for you, particularly Type I cannabis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 1, 2019
For a business which has decided to publish ads for cannabis businesses, there are a number of steps that would minimize the risk of receiving a call from a federal prosecutor or a visit from your local DEA agent. Sacco, Drug Enforcement in the United States: History, Policy, and Trends, Congressional Research Service (Oct.
The Cannigma
FEBRUARY 16, 2022
Listen & Subscribe: In light of Black History Month, we feel it is important and relevant to talk about how minorities in the United States and around the world have been disproportionately affected by drug policy and the war on drugs. EG: So, it is February, which means it’s Black History Month in the US right, Codi?
Cannabis Law Report
SEPTEMBER 23, 2019
Cannabis use, both medically and recreationally, is prevalent throughout history. Due to the Schedule I classification by the Drug Enforcement Agency (DEA), researchers seeking to investigate health effects associated with cannabis must follow a regimented application process. Background. Extensive evidence. 1 In the U.S. References.
Expert insights. Personalized for you.
52 
Let's personalize your content